The 2022 Supporter Survey results are in.
Read MoreThe 2022 Supporter Survey results are in.
Read MoreSpecsavers and Macular Disease Foundation Australia have begun a strategic scoping partnership.
Read MoreResearchers confirm the AREDS2 formulation is safe for use over a decade.
Read MoreFaricimab has taken one step closer towards clinics in Australia.
Read MoreMDFA strives to address challenges for people receiving intravitreal injections.
Read MoreThe Macula Month edition of Macula Matters, MDFA’s newsletter for healthcare professionals.
Read MoreSpecsavers and MDFA have announced a strategic scoping partnership with a vision to increase and enhance support for patients diagnosed with wet AMD.
Read MoreStudy reports impact of GA on independence and quality of life worse than expected
Read MoreHow MDFA is working with GPs, pharmacists and Aboriginal health workers
Read More